Recombinant Yersinia pseudotuberculosis serotype O:3 ATP synthase subunit alpha (atpA), partial

Introduction

Recombinant Yersinia pseudotuberculosis serotype O:3 ATP synthase subunit alpha (atpA), partial, refers to a genetically engineered fragment of the ATP synthase alpha subunit derived from the enteropathogen Y. pseudotuberculosis serotype O:3. ATP synthase is a critical enzyme complex in bacterial energy metabolism, catalyzing ATP production via oxidative phosphorylation. The alpha subunit (atpA) forms part of the F1 sector of the ATP synthase complex and plays a role in nucleotide binding and catalytic activity.

Biological Role of ATP Synthase Subunit Alpha (atpA)

ATP synthase in Yersinia species is essential for survival under aerobic and anaerobic conditions. The alpha subunit (encoded by atpA) contributes to the structural integrity of the F1Fo ATP synthase complex, facilitating proton gradient-driven ATP synthesis. Key features include:

• Functional Domains: The alpha subunit contains nucleotide-binding regions critical for ATP hydrolysis/synthesis.

• Metabolic Importance: ATP synthase enables Y. pseudotuberculosis to generate energy during host infection and environmental survival.

Recombinant Expression and Applications

Recombinant atpA is typically produced in heterologous systems (e.g., E. coli) for structural, functional, or immunological studies. Partial sequences may exclude transmembrane regions for soluble expression. Applications include:

• Antigen Production: Used to generate antibodies for diagnostic tools or vaccine development.

• Enzymatic Studies: Investigating ATP synthase inhibition as a potential antimicrobial strategy.

Table 1: Comparative Analysis of ATP Synthase Genes in Yersinia

Key Observations:

• ATP synthase is a target for antimicrobials (e.g., ciprofloxacin resistance mechanisms involve metabolic stress responses linked to ATP synthesis ).

• Y. pseudotuberculosis prioritizes energy metabolism during infection, as seen in transcriptomic studies under host-mimicking conditions .

Challenges and Future Directions

• Structural Characterization: High-resolution studies of recombinant atpA could reveal drug-targetable sites.

• Vaccine Development: Partial atpA fragments may serve as antigens for cross-protective vaccines, similar to strategies used for T3SS proteins like YopE-LcrV .